Aquinox(NLTX) - 2025 Q1 - Quarterly Results

Form 8-K Current Report (May 9, 2025) Report Overview and Registrant Information This section details the Form 8-K filing for Neurogene Inc., including the May 9, 2025 report date, company specifics, and Nasdaq Global Market listing under NGNE - This Current Report on Form 8-K was filed by Neurogene Inc. for the event date of May 9, 2025[2] Trading Information | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :--- | :--- | :--- | | Common Stock, $0.000001 par value | NGNE | The Nasdaq Global Market | Item 2.02 Results of Operations and Financial Condition Neurogene Inc. announced its Q1 2025 financial results via a May 9, 2025 press release, furnished as Exhibit 99.1, limiting Section 18 liability - On May 9, 2025, Neurogene Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025[5] - The information in the press release (Exhibit 99.1) is being "furnished" and not deemed "filed" under the Securities Exchange Act, which limits its legal liability under Section 18 of the Act[6] Item 9.01 Financial Statements and Exhibits This section details the exhibits accompanying the Form 8-K filing, primarily the May 9, 2025 press release (Exhibit 99.1) containing financial results Exhibits | Exhibit Number | Description | | :--- | :--- | | 99.1 | Press Release dated May 9, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Signatures The report is signed and authorized by Christine Mikail, President and Chief Financial Officer of Neurogene Inc., on May 9, 2025 - The report was signed on May 9, 2025, by Christine Mikail, President and Chief Financial Officer of Neurogene Inc[11]